Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, ...

“These data from the MajesTEC-5 study build on the growing body of evidence of teclistamab combinations that support the potential combinability of teclistamab with other effective ...

OPTec study 1 evaluates the use of prophylactic tocilizumab in patients with relapsed/refractory multiple myeloma receiving the bispecific antibody teclistamab. Initial results suggest ...

NICE has recommended teclistamab as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome ...

BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI ® (teclistamab) from two ...

"These data from the MajesTEC-5 study build on the growing body of evidence of TECVAYLI combinations that support the potential combinability of TECVAYLI with other effective therapies ...

About MajesTEC-5 StudyMajesTEC-5 (NCT05695508) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with newly ...

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy "These data from the ...

"These data from the MajesTEC-5 study build on the growing body of evidence of teclistamab combinations that support the potential combinability of teclistamab with other effective therapies, ...

For more information, visit https://www.darzalexhcp.com. TECVAYLI® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment ...